The difference between groups is statistically significant (HR = 0.89, 95%CI: 0.83∼0.94, p < 0.00001), it suggests that the efficacy of PD-1/PD-L1 in the treatment of NSCLC is better than docetaxel chemotherapy (Figure 5 Comparison of progression-free survival between groups). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.